UCB First Three Months Interim Report 2018: UCB tracking well towards full year financial outlook |
Brussels (Belgium), 25 April 2018 – 18:00 (CEST) – regulated information – - Revenue reached € 1.07 billion: -5%, -1% CER; adjusted for allergy drug divestiture in 2017: +0%; +4% CER
- UCB’s main five products reached € 839 million (-2%, +8% CER)
- R&D update: Cimzia® available for women with chronic inflammatory disease throughout the pregnancy journey; UCB0107 enters clinical phase 1; Element Genomics strengthens research platform; agreement to acquire midazolam nasal spray in epilepsy
- Financial outlook 2018 confirmed: Revenue expected to reach € 4.5 - 4.6 billion, recurring EBITDA2 should reach € 1.3 - 1.4 billion, Core EPS of € 4.30 - 4.70
|
Open PDF of "UCB First Three Month Interim Report 2018 ENG"
Open PDF of "UCB First Three Month Interim Report 2018 FR"
Open PDF of "UCB First Three Month Interim Report 2018 NL"
If you would rather not receive future communications from UCB SA, let us know by clicking
here.UCB SA, Allée de la Recherche, 60 ., Brussels, . B - 1070 Belgium